Mirum Pharmaceuticals, Inc. (MIRM) Stock Analysis & Investment Frameworks
Mirum Pharmaceuticals, Inc. (MIRM) stock analysis on Invetso. Review Mirum Pharmaceuticals, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Mirum Pharmaceuticals, Inc. Company Overview
- Exchange: NASDAQ Global Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Mirum Pharmaceuticals, Inc. Key Financial Metrics
- Market Cap: $6.09B
- Revenue: $521.31M
- ROE: -734.00%
- ROIC: -22.79%
- Dividend Yield: N/A
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.